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Abstract
Background: Over-expression of HER2 in a subset of breast cancers (HER2+) is associated with high histological
grade and aggressive clinical course. Despite these distinctive features, the differences in response of HER2+
patients to both adjuvant cytotoxic chemotherapy and targeted therapy (e.g. trastuzumab) suggests that
unrecognized biologic and clinical diversity is confounding treatment strategies. Furthermore, the small but
established risk of cardiac morbidity with trastuzumab therapy compels efforts towards the identification of
biomarkers that might help stratify patients.
Methods: A single institution tissue array cohort assembled at the Clearview Cancer Institute of Huntsville (CCIH)
was screened by immunohistochemistry staining using a large number of novel and commercially available
antibodies to identify those with a univariate association with clinical outcome in HER2+ patients. Staining with
antibody directed at TRMT2A was found to be strongly associated with outcome in HER2+ patients. This
association with outcome was tested in two independent validation cohorts; an existing staining dataset derived
from tissue assembled at the Cleveland Clinic Foundation (CCF), and in a new retrospective study performed by
staining archived paraffin blocks available at the Roswell Park Cancer Institute (RPCI).
Results: TRMT2A staining showed a strong correlation with likelihood of recurrence at five years in 67 HER2+
patients from the CCIH discovery cohort (HR 7.0; 95% CI 2.4 to 20.1, p < 0.0004). This association with outcome
was confirmed using 75 HER2+ patients from the CCF cohort (HR 3.6; 95% CI 1.3 to 10.2, p < 0.02) and 64 patients
from the RPCI cohort (HR 3.4; 95% CI 1.3-8.9, p < 0.02). In bivariable analysis the association with outcome was
independent of grade, tumor size, nodal status and the administration of conventional adjuvant chemotherapy in
the CCIH and RPCI cohorts.
Conclusions: Studies from three independent single institution cohorts support TRMT2A protein expression as a
biomarker of increased risk of recurrence in HER2+ breast cancer patients. These results suggest that TRMT2A
expression should be further studied in the clinical trial setting to explore its predictive power for response to
adjuvant cytotoxic chemotherapy in combination with HER2 targeted therapy.
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A major challenge in the treatment of breast cancer is
to accurately identify those patients who are more likely
to develop recurrence so that appropriate therapy can
be selected. Significant advances have been made in the
development of combination chemotherapy regimens
along with the development of effective targeted thera-
peutics [1]. However, the selection of patients who are
likely to benefit from such treatment remains challen-
ging and has necessitated a search for new molecular
biomarkers which could help to better predict the likeli-
hood of recurrence as well as the potential benefit from
such adjuvant treatment approaches.
The HER2 gene is amplified in 15-20% of breast can-
cers and this molecular alteration carries with it a more
aggressive clinical course [2-4]. A HER2 targeted mono-
clonal antibody, Trastuzumab, has been evaluated in
four large randomized clinical trials demonstrating sig-
nificant benefits in disease free survival (DFS) with the
addition of one year of Trastuzumab to adjuvant che-
motherapy [5,6]. However there appears to be clinical
heterogeneity in the response to Trastuzamab with a
significant number of patients demonstrating either de
novo or acquired resistance [6,7]. In addition, a risk of
cardiotoxicity has been identified in patients treated
with adjuvant Trastuzumab, especially following adju-
vant anthracyclines, which may be irreversible in small
fraction of patients [8,9]. Given the small but conse-
quential risk of cardiac morbidity associated with Tras-
tuzumab treatment, even in patients with normal
baseline cardiac function, there could be a clinical bene-
fit to identifying early stage patients at relatively high
risk of recurrence in order to better weigh the risk ver-
sus benefit of Trastuzumab treatment.
The clinical heterogeneity of HER2 positive tumors is
in part reflected in biologic heterogeneity as assessed by
gene expression profiling [10-12]. HER2 positive tumors
identified with immunohistochemistry and/or fluores-
cence in situ hybridization exhibit variation in global
gene expression patterns related in part to expression of
hormone receptor related genes and/or signatures that
distinguish the aggressive luminal B tumor subtype [13].
Estrogen receptor expression has been investigated as a
clinically useful classifier for HER2 positive patients but
has shown inconsistent results [14]. However, the hor-
mone receptor status of breast cancer does not appear
to influence the likelihood of clinical benefit from tras-
tuzumab therapy for HER2 positive tumors [5,15].
We have endeavored to translate gene expression
based classification of carcinoma into IHC reagents that
can be used to discover and validate the relationship
between tumor classification and clinically significant
phenotypes [16]. In the current study, we sought to
investigate candidate IHC markers that could better
define HER2 biologic diversity and or stratify HER2+
breast cancer into significantly different prognostic cate-
gories. We previously screened a large number of novel
commercially available antisera, targeted by gene expres-
sion data, to identify panels of antibodies useful for
breast tumor classification [16]. In this study, we quer-
ied this dataset for biomarkers associated with outcome
in HER2 expressing tumors and identified TRMT2A
(previously known as HTF9C), a novel cell cycle regu-
lated protein, as associated with aggressive clinical
course [16,17]. We confirm this association in two inde-
pendent clinical cohorts. The identification of a biomar-
ker that reproducibly stratifies HER2 positive breast
cancer patients into groups with different clinical out-
comes may aid clinical decision-making. Furthermore,
TRMT2A is a strong candidate biomarker worthy of
further investigation as a predictive marker of response
to adjuvant chemotherapy and HER2 targeted therapy.
Methods
Patient samples
Single institutional breast cancer cohorts from the Clear-
view Cancer Institute of Huntsville (CCIH), Cleveland
Clinic Foundation (CCF), and Roswell Park Cancer Insti-
tute (RPCI) were used in this study. In all cohorts, patient
tumor paraffin blocks were assigned an anonymous
unique identifier linked to a clinical data base that con-
tained treatment and outcome data blinded to investiga-
tors in this study. IRB approval was obtained for the use of
patient blocks at each respective institute. Patients were
excluded for study if they were male, had metastatic or
multicentric disease at time of diagnosis, or had received
trastuzumab in an adjuvant setting. Some study patients
were treated variably with adjuvant cytotoxic chemother-
apy. 67 HER2+a n d7 5HER2+ cases were identified by
IHC staining in the CCIH and CCF tissue arrays. The
RPCI cohort was assembled by retrospective review of the
pathology archives from January 1996 to January, 2006 to
identify HER2+ breast cancer patients who where 3+ posi-
tive by immunohistochemistry using the Herceptest™ test
kit (Dako, Carpenteria Ca). HER2 IHC status for all sixty-
four cases identified was confirmed by re-staining. The
clinicopathologic characteristics for the three patient
cohorts are summarized in table 1. For the purpose of gen-
erating clinical datasets, patients were censored at the time
of contralateral breast cancer diagnosis, diagnosis of a new
primary, or at the time of their last visit for patients clini-
cally evaluated as disease free.
Tissue arrays and immunohistochemistry
Each tissue microarray (TMA) block contained a single
0.6 mm core sampled from representative paraffin
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paraffinized and dehydrated by submerging in xylene
three times for 10 minutes each, followed by rinsing
three times in 100% ethanol, two times in 95% ethanol
and then treated by microwaving boiling for 11 minutes
in 10 uM buffered citrate pH 6.0. Slides were allowed to
cool to room temperature, and rinsed in distilled water
followed by PBS. Slides were dipped in 0.03% hydrogen
peroxide followed by rinsing with PBS and then stained
using dilutions of antibodies in DAKO Diluent (DAKO
Cytomation Inc.) for one hour at room temperature.
Initial studies were performed with rabbit polyclonal
affinity purified antibodies targeting a peptide located in
the amino terminal third of the protein (s0545). A novel
rabbit monoclonal antibody (S0722) directed to the
same peptide was generated which showed very similar
staining pattern to the polyclonal antibody as judged by
comparison across a large breast cancer tissue array
cohort (data not shown). The RPCI staining was per-
formed using the rabbit monoclonal antibody. For each
antibody, dilutions were first tested on a small ‘titer’ tis-
sue array that had breast cancer cases with positive and
negative cases in addition to a set of tumor derived cell
lines suspended in paraffin. Secondary antibody was
applied for one hour, and staining visualized using the
DAKO Cytomation Envision staining kit according to
the manufacturer’s instructions. Casesw e r ec o n s i d e r e d
TRMT2A expressing if greater than 10% of cells showed
cytoplasmic staining. Most positive cases show uniform
staining across tumor cells within the sample. Nuclear
staining in the absence of cytoplasmic staining was not
scored as positive (16).
Western Blots
Equal concentration of total cell line extracts from
UACC62, MOLT4, LOXIMVI, RXF393, and OVCAR5
or recombinant, e.coli produced protein encoding four
different human proteins (AbNova Inc) were run on a
denaturing polyacrylamide gel, transferred to blotting
paper. Blots were exposed to either a monoclonal anti-
body (s0722) directed at a synthetic peptide encoded
within TRMT2A amino terminal third of the protein, a
polyclonal antibody directed at the same peptide
(s0545), or an independent polyclonal affinity-purified
antibody (s0728) directed at a distinct, non-overlapping
peptide in the middle third of the protein.
Discovery and validation of HER2 prognostic biomarker
We previously reported the screening of 126 novel and
commercially available antibodies on the CCIH tissue
array [16]. Prior to the analysis performed in this manu-
script, thirty seven of these antibodies were selected for
staining of the CCF tissue array cohort solely on the
basis of a subjective assessment of staining quality and
sub-classification of breast cancer cases in the CCIH
cohort. In order to identify biomarkers associated with
outcome in the CCIH cohort, Cox proportional hazard
analysis was used to identify the subset of these thirty-
seven markers that had a univariate association of IHC
staining with recurrence-free interval (distant and local
recurrence) at 5 years. Antibody directed at TRMT2A
was identified as the single marker associated with out-
come in HER2+ patients. The hypothesis that TRMT2A
was related to outcome in HER2+ patients was subse-
quently evaluated in the existing CCF staining dataset as
Table 1 Clinical and Pathologic Features of Study
Patients
CCIH CCF RPCI
Total Her2+ Total Her2+ Her2+
ER N 452 69 240 81 64
+ 311 38 186 59 32
- 135 31 42 20 28
n/a 6 0 12 2 4
PR + 234 20 128 30 10
- 204 48 104 48 46
n/a 14 1 8 3 8
Age Mean 58 56 62 61 56
<50 132 25 57 25 23
> = 50 320 44 183 56 41
Nodal Stage 0 259 34 135 52 23
1 176 32 56 16 31
28 3 2 4 1 0 5
30 0 8 2 3
n/a 9 0 17 1 2
Tumor Stage 1 234 26 133 42 29
2 168 35 83 29 22
32 1 2 1 2 4 5
41 2 4 1 0 5 5
n/a 17 2 2 1 3
Clinical Stage 1 172 19 90 31 15
2A 133 19 62 27 23
2B 92 21 26 7 11
3A 15 1 27 9 7
3B 16 7 8 4 3
3C 0 0 8 2 3
n/a 24 2 19 1 2
Grade 1 69 5 31 7 4
2 175 21 101 35 22
3 162 32 72 34 35
n/a 90 11 36 5 3
Chemo None 250 28 115 31 18
Adjuvant 241 41 74 22 45
n/a 5 0 51 28 1
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was assembled explicitly to test the association identified
and confirmed in the CCIH and CCF cohorts respec-
tively. Staining was completed and scores were attached
to the patient code number by the pathology group
before the clinical records were linked to the immuno-
histochemistry dataset by the clinical investigator.
Statistical Considerations
The relationship between all recurrence within five years
of diagnosis and TRMT2A staining in HER2+p a t i e n t s
was assessed by a Cox proportional hazards model. Inde-
pendence of TRMT2A from other clinical and pathologic
prognostic parameters was also tested via Cox propor-
tional hazards with each variable in a bi- or multivariable
model. All univariate and multivariable Cox proportional
hazard ratios and associated p-values were calculated
using S-plus software (Tibco Software, Palo Alto, Califor-
nia). All reported p values are two sided.
Results
Discovery study
We previously described a breast cancer TMA
assembled from archived tumor samples seen at a regio-
nal cancer referral center, the Clearview Cancer Institute
of Huntsville (CCIH) that included 69 HER2 expressing
cases. As part of a large project aimed at translating the
emerging gene expression based classification of carci-
noma into an IHC-based classification, we had screened
a large number of novel polyclonal affinity-purified anti-
bodies for association with clinical outcome and selected
thirty-seven for further study in an independent cohort
assembled at the Cleveland Clinic Foundation (CCF)
[16]. Of these thirty-seven antibodies, only antibody tar-
geting TRMT2A showed a strong correlation with likeli-
hood of recurrence at five years in HER2 positive
patients (HR 7.0; 95% CI 2.4 to 20.1, p < 0.0004) in the
CCIH cohort (figure 1A). TRMT2A stained cases
showed a strong uniform granular cytoplasmic staining
of tumor cells (Figure 2). Occasional cases show some
staining of nuclei, but only the presence of cytoplasmic
staining was considered for the purpose of assessing
staining with TRMT2A. Nodal status but not tumor size
was associated with outcome in HER2 expressing
patients in this cohort (Table 2).
Validation studies
We prospectively designated TRMT2A as a candidate
biomarker for validation in silico in the existing CCF
cohort dataset which confirmed the association between
TRMT2A staining and poor outcome (HR 3.6; 95%
CI 1.3 to 10.2, p < 0.02) (Figure 1B). We subsequently
assessed data generated using all remaining thirty-six
biomarkers and found that in addition to TRMT2A,
both estrogen receptor and progesterone receptor
expression were associated with outcome in this cohort.
Neither pathologic or clinical stage were associated with
outcome in this cohort.
The identification of an association between TRMT2A
expression and outcome in two independent cohorts
encouraged us to explore the association in a novel
third independent cohort assembled at the RPCI. Within
this cohort, only grade was associated with outcome in
HER2 expressing patients while estrogen receptor,
Figure 1 Kaplan-Meier survival curves for HER2 positive breast
cancer cases stratified by staining with antibody directed at
TRMT2A. TRMT2A expression is associated with outcome in a) the
CCIH training cohort, b), the CCF confirmation cohort, and c) the
RPCI validation cohort.
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with cytotoxic chemotherapy were not. We used a new
rabbit monoclonal antibody directed at TRMT2A
(S0722) which stained in a pattern very similar to the
original polyclonal reagent across the CCIH cohort (data
not shown). Western blot analysis with the rabbit mono-
clonal antibody showed an identical 38KD bands on
multiple cell lines as the original polyclonal antibody
and the same molecular weight band as a second poly-
clonal affinity purified antibody (s0728) directed at an
independent epitope within the TRMT2A predicted pro-
tein. It also recognized only its cognate 68 kd in vitro
transcribed and translated fusion protein in a western
blot of four different fusion proteins loaded in equimo-
lar amounts (figure 3). Cytoplasmic staining with the
monoclonal reagent was highly associated with disease
recurrence in the RPCI cohort (HR 3.42; 95%CI 1.3-8.9,
p < 0.02) (Figure 1C).
In these three institutional cohorts from CCIH, CCF,
and RPCI, TRMT2A stained 29%, 37% and 23% respec-
tively. However, these subsets of patients contained 69%,
59% and 47% of the total number of HER2+p a t i e n t s
that recurred. Within the CCIH and CCF cohorts,
where comparison with HER2- patients was possible, the
five year recurrence rate of HER2+/TRMT2A-patients
was lower than that of HER2- patients (CCIH:10% ver-
sus 19%, CCF: 12% versus 17%).
To assess whether TRMT2A was providing informa-
tion in HER2 expressing patients that was independent
of standard clinical and pathologic factors in addition to
ER and PR staining, we performed univariate and bivari-
ate analysis with each prognostic factor and outcome
(Table 2). While TRMT2A was independent of each of
these factors in the CCIH and RPCI cohorts, it was
only independent of grade and age in the CCF cohort
Table 2 Clinical and pathologic prognostic factors in the clinical cohorts
CCIH CCF RPCI
Univariate
HR
Factor
Bivariate HR
TRMT2A
Bivariate HR
Univariate
HR
Factor
Bivariate HR
TRMT2A
Bivariate HR
Univariate
HR
Factor
Bivariate HR
TRMT2A
Bivariate HR
ER 0.435
(0.11)
1.05 (0.93) 7.15 (0.0012) 0.293
(0.014)
0.233 (0.044) 1.415 (0.63) 0.471
(0.13)
0.573 (0.3) 2.573 (0.066)
PR 0.347
(0.16)
1.04 (0.97) 7.08 (0.0024) 0.205
(0.036)
0.143 (0.066) 2.703 (0.082) 0.18 (0.1) 0 (0.73) 2.8 (0.058)
Age 1.01 (0.52) 1.01 (0.61) 6.91 (0.00035) 0.982 (0.29) 0.974 (0.15) 3.457 (0.02) 1 (0.87) 1 (0.85) 3.39 (0.013)
N
Stage
4.16
(0.00043)
3.9 (0.0027) 5.63 (0.0015) 2.47
(0.0001)
2.41 (0.0002) 2.03 (0.23) 1.17 (0.52) 1.37 (0.3) 3.33 (0.014)
T
Stage
1.2 (0.54) 1.07 (0.85) 6.93 (0.00046) 2.34
(0.0001)
2.72 (0.0001) 2.31 (0.13) 1.24 (0.26) 1.14 (0.56) 3.35 (0.014)
Grade 0.869
(0.74)
0.805 (0.59) 12.25 (0.00018) 2.16 (0.079) 2.35 (0.092) 2.79 (0.058) 3.5 (0.018) 2.96 (0.077) 3.34 (0.017)
Chemo 1.64 (0.36) 0.925 (0.89) 7.14 (0.0005) 8.78
(0.0048)
15.13 (0.0098) 2.23 (0.17) 1.46 (0.42) 1 (0.99) 3.34 (0.014)
Hazard ratios (p-values) of common prognostic factors within the Her2+ patients in each of the three cohorts. The first column reports each factor as univariate
HR’s whereas the second and third column reports each factor and TRMT2A respectively as bivariate HR’s.
Figure 2 Immunohistochemical staining of HER2 + breast
cancer with monoclonal anti-TRMT2A (S0722).
Figure 3 Western blot staining with anti-TRMT2A antibodies.a .
Monoclonal antibody (S0722) directed at TRMT2A recognizes 38 Kd
bands in five cell lines. b. Affinity purified polyclonal antibody
(s0728) directed at a different, non-overlapping peptide in TRMT2A
compared to the monoclonal also recognizes a 38 Kd band in the
same cell lines. c. Polyclonal antibody to the same peptide as used
to generate the monoclonal (s0545) stains only recombinant
produced TRMT2A and not other recombinant proteins.
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univariate association with outcome. TRMT2A was
independent or near independent of ER and PR in all
three cohorts with the exception of ER in the CCF
cohort. By multivariable analysis TRMT2A was indepen-
dent of tumor size, nodal status and grade in both the
CCIH and RPCI cohorts (Table 3).
Discussion
In the current report, we have demonstrated in three inde-
pendent institutional cohorts that IHC-based detection of
cytoplasmic TRMT2A identifies a subset of HER2+
patients with a high likelihood of recurrence. In these
cohorts in which patients were treated with various cyto-
toxic chemotherapy regimens without Traztuzumab,
estrogen and progesterone receptor expression showed an
inconsistent relationship with outcome similar to inconsis-
tent finding in the published literature [13-15]. TRMT2A’s
association with outcome in bivariable analysis was inde-
pendent or near independent of both pathologic grade and
hormone receptor status. These findings suggest that
TRMT2A is a novel, independent biologic factor expressed
in tumors associated with clinical outcome in HER2
expressing breast cancer. Although the association
between TRMT2A expression and outcome was indepen-
dent of chemotherapy treatment, it should be noted that
as these cohorts were not derived from randomized trials
it remains unclear whether TRMT2A has primarily a
prognostic relationship to outcome or if it is predictive of
response to therapy.
TRMT2A was chosen for study based upon its identifi-
cation as a novel open reading frame whose expression
varies during the cell cycle similar to the oscillation of
MCM, tubulin, CDC2, and other genes whose expression
peak in S-phase and decrease during mitosis. Genes with
similar expression patterns have been noted to be
involved in different aspects of transiting the cell cycle
and certain members have been noted to be elevated
in tumor cells [17,18]. The function of TRMT2A, a
676 amino acid protein, is not known although by
sequence homology it has a domain related to RNA
methyltransferases [19]. Its expression has been pre-
viously shown to correlate with poor prognosis in ER+
breast cancer as a member of a validated, multivariate
index assay combining five IHC antibodies in a prognos-
tic test for Tamoxifen treated ER+ breast cancer [16,20].
When present in tumor cases, TRMT2A protein expres-
sion typically demonstrates a homogenous cytoplasmic
pattern with some additional staining of nuclei. Nuclear
staining alone is not associated with outcome (data not
shown) and is ignored for the purpose of pathologic eva-
luation. This raises the possibility that cytoplasmic
expression reflects a tumor specific aberrant expression
pattern. TRMT2A does not stain intermittent cycling
cells in a manner reminiscent of classic makers of prolif-
eration (e.g. KI67/Mib1 and PCNA). KI67/Mib1 staining
was not significantly prognostic is any of three her2
cohorts reported herein although its expression trended
towards an association with outcome (data not shown).
Therefore, TRMT2A appears to be measuring physiology
distinct from that measured by classic proliferation mar-
kers. Given TRMT2A’s strong prognostic association in
HER2 expressing patients and its periodic expression dur-
ing the cell cycle, it is interesting to speculate that
TRMT2A over-expression may reflect tumor cells driven
by an activated HER2 pathway towards aggressive growth.
Conclusion
A greater understanding of the biologic heterogeneity
within the HER2 positive cohort of breast cancers iden-
tified clinically would aid efforts to assess and predict
outcome for this important subset of patients. Further-
more, prudent selection of treatment regimen and
length of treatment could be helped by the identification
of biomarkers that identify patients with a more aggres-
sive clinical course as well as those most likely to
respond to adjuvant therapy. Our data suggests that
HER2+/TRMT2A+ breast cancers are more likely to
recur treated with traditional cytotoxic therapy alone
and therefore more aggressive treatment in the adjuvant
setting may need to be considered for these patients,
regardless of the other conventional risk factors.
W h e t h e ro rn o tHER2+/TRMT2A+ tumors are more
likely to show benefit from trastuzumab cannot be
determined from the current data but these data suggest
that it should be studied in the clinical trial setting to
further explore its relationship to response to adjuvant
cytotoxic chemotherapy and HER2 targeted therapy.
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